欢迎您访问《中华养生保健》官方网站!

中华养生保健 ›› 2023, Vol. 41 ›› Issue (12): 1-4.

• 论著 •    下一篇

安多霖对食管鳞癌放疗期间骨髓抑制程度影响的研究

路鹏霏, 贾春丽, 吴戈, 张华   

  1. 新疆维吾尔自治区新疆医科大学第一附属医院肿瘤二科,新疆 乌鲁木齐,830011
  • 发布日期:2023-06-07
  • 作者简介:路鹏霏(1991—),男,汉族,籍贯:新疆维吾尔自治区克拉玛依市,博士研究生,住院医师,研究方向:消化系统肿瘤疾病诊疗。
  • 基金资助:
    国家重点研发计划课题(2017YFC0909903); 中华医学会临床医学科研专项资金——扬子江镇痛研究与发展项目(19010020771)

Study of the Effect of Andolin on the Degree of Bone Marrow Suppression during Radiotherapy for Esophageal Squamous Cell Carcinoma

LU Peng-fei, JIA Chun-li, WU Ge, ZHANG Hua   

  1. Department of Oncology, First affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous region, Urumqi Xinjiang 830011, China
  • Published:2023-06-07

摘要: 目的 探讨使用安多霖胶囊对食管癌患者放疗期间骨髓抑制情况的影响。方法 收集新疆医科大学第一附属医院2018年1月—2018年12月96例食管鳞癌单纯放疗的患者资料,放射剂量在50~60 Gy,其中有46例患者在放疗期间口服安多霖胶囊4粒/次,3次/d,连续口服直至放疗结束;其余50例患者放疗期间未服用任何药物。每隔5 d测血常规1次,观察患者的血常规变化情况。通过白细胞计数水平、血红蛋白水平及血小板水平监测患者放疗期间骨髓抑制情况。结果 96例患者中,68例男性,28例女性;50.0%的病例病变部位位于胸中段;Ⅰ、Ⅱ、Ⅲ、Ⅳ期患者分别占2.1%、5.2%、59.4%、33.3%。放疗期间使用安多霖胶囊的患者多为Ⅰ度骨髓抑制,而未使用任何药物的患者骨髓抑制程度多为Ⅱ度。使用安多霖胶囊患者的白细胞计数在(4.02±1.67)×109/L,而未使用组在(3.23±1.34)×109/L(P=0.012),血小板计数水平使用组在(150.26±84.46)×109/L,而未使用组在(108.70±58.56)×109/L(P=0.006)。结论 使用安多霖对食管鳞癌单纯放疗患者具有潜在的减弱骨髓抑制反应的作用,且以血小板计数水平反应最为明显。

关键词: 安多霖, 食管鳞癌, 单纯放疗, 血象, 骨髓抑制

Abstract: Objective To investigate the effect of Anduolin capsule on myelosuppression in patients with esophageal cancer during radiotherapy. Methods 96 patients with esophageal cancer were treated with radiotherapy alone in the first affiliated Hospital of Xinjiang Medical University, the radiation dose was 50~60 Gy, among them, 46 patients took Anduolin capsule 4 capsules per time, 3 times a day, continuously until the end of radiotherapy, and the other 50 patients did not take any drugs during radiotherapy. The blood routine was every 5 days, and the changes of hemogram of the patients were observed. The level of leukocyte, hemoglobin and platelet were used to monitor the myelosuppression during radiotherapy. Results Among the 96 patients, there were 68 cases of male and 28 cases of male and female. Most of the lesions were located in the middle part of the chest, accounting for 50.0%, and the PS scores of the patients were all 1, of which the Han nationality was the most, accounting for 46.9%, followed by the Kazakh nationality (32.3%), while patients with stage Ⅰ, Ⅱ, Ⅲ and Ⅳ accounted for 2.1%, 5.2%, 59.4% and 33.3%, respectively. Most of the patients who took Anduolin capsule during radiotherapy had first-degree myelosuppression, while those who did not use any drugs mostly had second-degree myelosuppression. The white blood cell count of the patients treated with Anduolin capsule was (4.02 ±1.67) ×109/L, while that of the unused group was (3.23 ±1.34) ×109/L, and the level of platelet count was (150.26±84.46) ×109/L in the use group, and(108.70±58.56) ×109/L in the non-use group. Conclusion The use of Anduolin could reduce the reaction of myelosuppression in patients with esophageal cancer treated with radiotherapy alone, especially at the level of white blood cell count.

Key words: anduolin, esophageal cancer, radiotherapy alone, hemogram, myelosuppression

中图分类号: